- EDS patients undergoing HA + PAO achieved significant improvements in function, pain, and mental health measured by iHOT-12, PROMIS-PF, and Pain Interference.
- Satisfaction exceeded 80% at one and two years in both EDS and non-EDS cohorts, despite lower absolute functional gains in EDS patients.
- EDS patients had lower PROMIS-PF absolute PASS and maximal outcome improvement (43% vs 78%), yet PROMIS-Depression PASS was higher (87% vs 57.5%).
Arthroscopy. 2026 Sep 22. doi: 10.1002/arj.70608. Online ahead of print.
ABSTRACT
PURPOSE: To define clinically meaningful outcomes after hip arthroscopy (HA) with periacetabular osteotomy (PAO), HA + PAO in patients with Ehlers-Danlos syndrome (EDS) using the Patient-Reported Outcomes Measurement Information System (PROMIS) and International Hip Outcome Tool 12 (iHOT-12) and compare these with a non-EDS cohort.
METHODS: Prospectively collected data from patients undergoing HA + PAO between 2018 and 2023 at tertiary hip preservation centers with dedicated referral populations for EDS were retrospectively analyzed. Patients with hip dysplasia or instability and ≥2-year follow-up were included. All patients in the EDS cohort had been diagnosed by an outside provider with either a nongenetic or genetic subtype of EDS. The non-EDS group was constructed as a comparison cohort selected to approximate the EDS group. Outcome measures included iHOT-12 and PROMIS computer adaptive tests: Physical Function (PF), Global Physical Health, Global Mental Health, and Pain Interference. Minimal Clinically Important Difference, Patient Acceptable Symptom State (PASS), and Maximal Outcome Improvement were calculated for these measures.
RESULTS: The non-EDS cohort included 103 patients, and the EDS cohort included 26. The mean ± standard deviation age was 25.1 ± 4.2 and 28.7 ± 6.2 (P = .01) for the non-EDS and EDS groups, respectively. Both groups reported >80% satisfaction at 1 and 2 years. Minimal Clinically Important Difference values for the iHOT-12, PROMIS-PF, and PROMIS-Depression in the non-EDS cohort were 13.7, 4.4, and 4.4 at 1 year and 11.2, 3.5, and 4.6 at 2 years, respectively. Minimal Clinically Important Difference agreement analysis was comparable between groups. However, EDS patients showed lower absolute PASS and Maximal Outcome Improvement agreement, particularly for PROMIS-PF, with 43% of EDS patients achieving 1-year absolute PASS compared with 78% of non-EDS patients. PROMIS-Depression outcomes showed a higher absolute PASS agreement in EDS patients with 87% achieving this outcome compared with 57.5% in the non-EDS cohort.
CONCLUSIONS: Patients with EDS undergoing HA + PAO achieve significant improvements in function, pain, and mental health, as measured by iHOT-12, PROMIS-PF, and PROMIS-Pain Interference. Despite lower PROMIS-PF gains compared with non-EDS patients, satisfaction and clinically meaningful outcomes are comparable.
LEVEL OF EVIDENCE: Level III, comparative retrospective study.
PMID:42770776 | DOI:10.1002/arj.70608
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
